These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15102665)

  • 1. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
    Mackay HJ; Hoekstra R; Eskens FA; Loos WJ; Crawford D; Voi M; Van Vreckem A; Evans TR; Verweij J
    Clin Cancer Res; 2004 Apr; 10(8):2636-44. PubMed ID: 15102665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
    Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
    Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
    Tabernero J; Rojo F; Marimón I; Voi M; Albanell J; Guix M; Vázquez F; Carulla J; Cooper M; Andreu J; Van Vreckem A; Bellmunt J; Manne V; Manning JA; Garrido C; Felip E; Del Campo JM; García M; Valverde S; Baselga J
    J Clin Oncol; 2005 Apr; 23(11):2521-33. PubMed ID: 15710949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
    Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
    Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
    Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
    Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
    Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
    Britten CD; Rowinsky EK; Soignet S; Patnaik A; Yao SL; Deutsch P; Lee Y; Lobell RB; Mazina KE; McCreery H; Pezzuli S; Spriggs D
    Clin Cancer Res; 2001 Dec; 7(12):3894-903. PubMed ID: 11751480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
    Moulder SL; Mahany JJ; Lush R; Rocha-Lima C; Langevin M; Ferrante KJ; Bartkowski LM; Kajiji SM; Noe DA; Paillet S; Sullivan DM
    Clin Cancer Res; 2004 Nov; 10(21):7127-35. PubMed ID: 15534083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
    Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
    Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
    Sun W; Stevenson JP; Gallagher ML; Vaughn D; Hahn SM; Haller DG; Cohen M; Kopit J; Gallant G; O'Dwyer PJ
    Clin Cancer Res; 2003 Nov; 9(14):5221-7. PubMed ID: 14614002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
    Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
    Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
    Eskens FA; Awada A; Cutler DL; de Jonge MJ; Luyten GP; Faber MN; Statkevich P; Sparreboom A; Verweij J; Hanauske AR; Piccart M;
    J Clin Oncol; 2001 Feb; 19(4):1167-75. PubMed ID: 11181683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers.
    MacKenzie MJ; Hirte HW; Siu LL; Gelmon K; Ptaszynski M; Fisher B; Eisenhauer E
    Ann Oncol; 2004 Apr; 15(4):665-70. PubMed ID: 15033677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.